Seagen (MEX:SGEN) Land And Improvements : MXN0 Mil (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Seagen Land And Improvements?

Seagen's land and improvements for the quarter that ended in Sep. 2023 was MXN0 Mil.

Seagen's annual land and improvements increased from Dec. 2020 (MXN95 Mil) to Dec. 2021 (MXN98 Mil) but then declined from Dec. 2021 (MXN98 Mil) to Dec. 2022 (MXN93 Mil).

Seagen Land And Improvements Historical Data

The historical data trend for Seagen's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seagen Land And Improvements Chart

Seagen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Land And Improvements

Get a 7-Day Free Trial

93.68

89.98

94.91

97.87

93.02

Seagen Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Land And Improvements	Get a 7-Day Free Trial															-	93.02	-	-	-

Seagen Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Seagen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seagen Inc (MEX:SGEN) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

21823 - 30th Drive South East, Bothell, WA, USA, 98021

Website

https://www.seagen.com

Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.